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This commentary reflects on the paper reports 
published in the Critical Care Forum between 
11 September 2001 and 5 November 2001
In the present issue of Critical Care the breadth of ongoing
research is reflected in the diversity of the subjects reported on.
More evidence regarding what we should and should not be
feeding our patients continues to emerge. A systematic review
of immunonutrition trials [1] concludes that this therapy is of no
benefit and may indeed be harmful. Outside the critical care
arena, however, there is evidence that specific dietary
supplements are beneficial, with cranberry juice lowering the
incidence of urinary tract infections in a susceptible population
[2]. Further trials of dietary supplements in critically ill patients
are underway, with ω-3 fatty acids attracting particular interest.
The value of enteral nutrition was reinforced by a study that
investigated risk factors for the development of decubitus
ulcers [3]. That report acts as a timely reminder that,
regardless of advances in cutting edge therapies (see below),
the quality of basic care must remain a priority. The most
striking finding of that study is the marked increase in
incidence (from 0.9 to 8.9% over the study period) – a
worrying but perhaps unavoidable reflection on the priorities of
care. Reducing the incidence of ileus in intensive care unit
patients may also be on the horizon with the first successful
trial of a new selective gastrointestinal opioid receptor blocker
in postoperative patients [4].
The optimal regimen of intravenous fluid replacement remains a
topic of considerable interest. Dr Venn discusses a paper by
Waters et al. [5], who conducted a randomized trial of normal
saline versus Ringer’s lactate and found no difference in
outcomes despite the propensity of normal saline to provoke
an iatrogenic hyperchloraemic acidosis. A new systematic
review of the use of albumin as an intravenous fluid therapy [6]
concludes that this intervention is not associated with an
excess mortality, unlike the previous and controversial
systematic review on this topic [7].
Another example of the hazards of technological innervations
has emerged from the introduction of automated taps that are
employed to reduce cross contamination when hand washing
[8]. Alarmingly, a study of the effectiveness of such devices
found that, rather than improving control of infection, they
actually act as a reservoir for intensive care unit pathogens, in
particular Pseudomonas aeruginosa and Legionella spp.
Although not reported on, the following may be of interest.
Sepsis research has suffered a further blow with the
disappointing results of the high-dose antithrombin III trial [9],
in which coadministration of heparin might have been
responsible for neutralizing the beneficial effects of this
therapy, and most certainly significantly increased the risk for
haemorrhage. On a more optimistic note, early experimental
work into the efficacy of a naturally occurring group of
compounds, the cecropins, that exhibit antiendotoxin activity
appears promising [10]. Finally, research into the optimal
diagnostic and therapeutic interventions for pulmonary
embolus are becoming apparent. The limitations of helical
computed tomography are reinforced by the findings of Perrier
et al. [11], whereas there appears to be no value of
thrombolysis over heparinization in haemodynamically stable
patients with massive pulmonary embolism [12].
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